NCT07458542 2026-03-09
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
Bristol-Myers Squibb
Active not recruiting
Clinical Trials
8 trialsNCT06565975 2026-02-12
RELION
Bristol-Myers Squibb
Completed
NCT06390306 2025-06-03
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Peking University People's Hospital
Recruiting
NCT06073769 2024-11-06
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
Bristol-Myers Squibb
Recruiting
NCT04230564 2023-06-07
Acute Myeloid Leukemia Real World Treatment Patterns
Pfizer
Withdrawn
NCT04296214 2021-07-09
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Withdrawn
NCT04454580 2020-09-16
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Ospedale Maggiore Di Trieste
Unknown
NCT03284593 2020-07-30
LAM-BDD
University Hospital, Toulouse
Active not recruiting